This new study sought to solidify a relationship between certain microbes in intestinal flora and the risk of developing myasthenia gravis, specifically those potentially reducing that risk.
Researchers were able to identify specific microbes associated with a higher risk of developing myasthenia gravis,1 a chronic autoimmune neuromuscular disease characterized by skeletal muscle weakness in which initial symptoms can present in the eye or face and throat muscles.2
Writing in Cell and Bioscience, the researchers noted that previous research demonstrates a potential relationship between gut microbiota and myasthenia gravis in human patients and animal models, but that causal data remain lacking.
“While suggesting an association between gut microbiota and myasthenia gravis, the conclusions drawn in observational studies tend to be based on ‘association’ rather than ‘causation,” they wrote. “Traditional epidemiological causal inference is hampered by reverse causation and confounding factors.” To overcome these obstacles, they used Mendelian randomization (MR), noting that the method helps to overcome these limitations by using gene variation as instrumental variables.
Woman using digital x-ray of human intestine holographic scan projection 3D rendering | Image Credit: sdecoret - stock.adobe.com
Genome-wide association study (GWAS) data were provided by the MiBioGen Consortium for the gut microbiota, which encompassed 16S ribosomal RNA gene sequencing and genotype data from 13,266 predominantly European participants for 211 bacterial characteristics belonging to 131 genera in 9 phyla with 16 classes, 20 orders, and 35 families. The FinnGen Research Project provided GWAS data on myasthenia gravis incidence (n = 426 diagnoses and 373,848 control patients).
Inverse variance weighted (IVW) analyses demonstrated that the following families of bacteria were associated with a lower risk of myasthenia gravis:
Four additional methods were used to decipher the gut microbiota–myasthenia gravis relationship, and their results echoed that of the IVW analysis and a lower risk of myasthenia gravis:
In contrast, a higher risk of myasthenia gravis was seen in connection with the genus Lachnoclostridium in all 5 models:
Next, the investigators conducted a reverse IVW analysis and found that having less of the genus Barnesiella was linked to increased odds of having myasthenia gravis with ORs of 0.945 (95% CI, 0.906-0.985; P = .008), 0.990 (95% CI, 0.871-1.126; P = .895), 0.946 (95% CI, 0.897-0.997; P = .039), 0.942 (95% CI, 0.880-1.009; P = .189), and 0.943 (95% CI, 0.888-1.001; P = .152), respectively.
The study investigators underscored that there are several theories on the pathogenesis of myasthenia gravis, including antibodies against acetylcholine receptors, the role of CD4+ T cells, and the impact of CD4+ T cell subtypes and cytokines, but that attention is increasingly being paid to intestinal flora. This is because of the potential for changes in microbial species or commensal communities “to play a therapeutic role in autoimmune diseases by altering the balance between pathogenic and protective immune responses.”
Rheumatoid arthritis and inflammatory bowel disease are 2 disease states that have seen improvements with gut microbiome changes, they added.3,4
They recommend that future basic and clinical studies be conducted to clarify the exact role that gut microbiota play in the development of myasthenia gravis, as well as the therapeutic potential of changes within in.
References
1. Su T, Yin X, Ren J, Lang Y, Zhang W, Cui L. Causal relationship between gut microbiota and myasthenia gravis: a bidirectional mendelian randomization study. Cell Biosci. 2023;13(1):204. doi:10.1186/s13578-023-01163-8
2. Myasthenia gravis. Mayo Clinic. June 22, 2023. Accessed November 14, 2023. https://www.mayoclinic.org/diseases-conditions/myasthenia-gravis/symptoms-causes/syc-20352036
3. So JS, Kwon HK, Lee CG, et al. Lactobacillus casei suppresses experimental arthritis by down-regulating T helper 1 effector functions. Mol Immunol. 2008;45(9):2690-2699. doi:10.1016/j.molimm.2007.12.010
4. Kim N, Kunisawa J, Kweon MN, Eog Ji G, Kiyono H. Oral feeding of Bifidobacterium bifidum (BGN4) prevents CD4(+) CD45RB(high) T cell–mediated inflammatory bowel disease by inhibition of disordered T cell activation. Clin Immunol. 2007;123(1):30-399. doi:10.1016/j.clim.2006.11.005
Patients With HFrEF, HFpEF See Different Functional Capacity Benefits With Dapagliflozin
December 7th 2023The DETERMINE-Reduced and DETERMINE-Preserved trials demonstrated varying benefits of dapagliflozin on Kansas City Cardiomyopathy Questionnaire Total Symptom Score and Physical Limitation Scale as well as 6-minute walk distance.
Read More
Black Patients With Ulcerative Colitis Less Likely to Undergo IPAA Than White Patients
December 7th 2023Overall, the number of patients discharged from hospitals with an ulcerative colitis diagnosis increased between 2009 and 2018, but the number of patients opting for ileal pouch–anal anastomosis (IPAA) decreased.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More